top of page


CEO & Director

Christopher has broad experience in early-stage pharmaceutical R&D and commercialisation in both private equity funded and listed companies.

He was Research Director and a Technology Founder at Antisense Therapeutics Ltd (ASX:ANP), a satellite company of RNA therapeutics leader Ionis Pharmaceuticals, and has guided RNA-targeting drugs from research through to the clinic and commercial exit.

In previous CEO roles he navigated a novel therapeutic entity (NTE) nasal spray product from concept through Phase 1b clinical trials and exit in 5 years (Otifex), and built a team and company structure that produced the most advanced direct Myc inhibitor for cancer (MycRx).

Christopher has a PhD in Biochemistry and an MBA specialising in Technology Management.  He was a Guest Scientist and Humboldt Fellow at the German Cancer Research Centre in Heidelberg, and in 2008 he received the Advance BioBusiness Award for leadership in the Australian Life Sciences sector.

CjW am Neckar May 2018 more bckgr.jpeg
Christopher Wraight: Our Team
bottom of page